Advertisement

Urological Research

, Volume 25, Supplement 1, pp S31–S35 | Cite as

Immunohistochemical determination of p53 overexpression

An easy and readily available method to identify progression in superficial bladder cancer?
  • F. C. Burkhard
  • R. Markwalder
  • G. N. Thalmann
  • U. E. Studer
Original Paper

Abstract

Overexpression of p53, as determined by immunohistochemical staining with the murine monoclonal antibody DO7, was determined in specimens of 46 primary superficial transitional cell bladder tumours (14 TaG2, 10 T1G2, 22 T1G3). A colon cancer specimen served as a positive control and normal mesenchymal cells in the specimens served as an internal negative control. An exceptionally high proportion 36/46 (78%) of the specimens were found to stain positively for p53 in over 20% of the cell nuclei. After a median follow-up of 7 years, ten patients developed progressive disease. Of these ten patients nine demonstrated p53 positivity, resulting in a sensitivity of 90%. However, 27 of the overall 36 patients (75%) with p53-positive tumours did not progress to a higher stage or metastatic disease. These findings suggest that p53 overexpression is not of predictive prognostic value in superficial transitional cell carcinoma. With 7 of 14 specimens (50%) of Ta tumours overexpressing p53, the results were suggestive of p53 mutation being an early event in carcinogenesis. When the threshold was set at 50% of the cell nuclei overexpressing p53, 16/46 (35%) classified as p53 positive. Of the 16 tumours staining positively for p53, 7 (46%) progressed and 9 (56%) did not. None of the Ta and 16 (50%) of the T1 tumours classified as positive. This more stringent definition of positivity still does not identify p53 positivity as a single prognostic factor. With 50% of T1 tumours classifying as positive, we still find that p53 mutation may be an early event in carcinogenesis of bladder cancer.

Key words

Bladder tumour Carcinogenesis p53 tumour-suppressor gene Disease progression Immunohistochemistry 

References

  1. 1.
    Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5PubMedGoogle Scholar
  2. 2.
    Beckstead JH (1994) Improved antigene retrieval in formalin-fixed, paraffin-embedded tissues. Appl Immunohistochem 2:274Google Scholar
  3. 3.
    Dalbagni G, Presti JC Jr, Reuter VE, Zhang ZF, Sarkis AS, Fari WR, Cordon-Cardo C (1994) Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 2:4Google Scholar
  4. 4.
    Esrig C, Spruck III CH, Nichols PW, Chaiwun B, Stevens K, Groshen S, Chen S, Skinner DG, Jones PA, Cote RJ (1993) P53 nuclear protein accumulation correlates with mutations in the p53 gene, tumour grade, and stage in bladder cancer. Am J Pathol 143:1389Google Scholar
  5. 5.
    Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen S-C, Nichols PW, Skinner DG, Jones PA, Cote RJ (1994) Accumulation of nuclear p53 and progression in bladder cancer. N Engl J Med 19:1259Google Scholar
  6. 6.
    Gan Y, Wientjes MG, Badalament RA, Au JL-S (1996) Pharmacodynamics of doxorubicin in human bladder tumours. Clin Cancer Res 2:1275PubMedGoogle Scholar
  7. 7.
    Gardiner RA, Walsh MD, Allen S, Rahman S, Samaratunge MLTH, Seymour GJ, Lavin MF (1994) Immunohistochemical expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol 73:526PubMedGoogle Scholar
  8. 8.
    Greenblatt MS, Benett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855PubMedGoogle Scholar
  9. 9.
    Harris CH, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318PubMedGoogle Scholar
  10. 10.
    Kuczyk MA, Serth J, Anton P, Höfner K, Jonas U (1994) Value of p53 immunohistochemistry as an independent prognosticator for superficial bladder cancer. Z Urologic Poster 2/1994Google Scholar
  11. 11.
    Lane DP (1992) P53, guardian of the genome. Nature 358:15PubMedGoogle Scholar
  12. 12.
    Levine AJ (1992) The p53 tumor-suppressor gene. N Engl J Med 326:1350PubMedGoogle Scholar
  13. 13.
    Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453PubMedGoogle Scholar
  14. 14.
    Marshall CJ (1991) Tumor suppressor genes. Cell 64:313PubMedGoogle Scholar
  15. 15.
    Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) Themdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237PubMedGoogle Scholar
  16. 16.
    Nakopoulou L, Constantinides C, Papandropoulos J, Theodoropoulos G, Tzonou A, Giannopoulos A, Zervas A, Dimopoulos C (1995) Evaluation of overexpression of p53 tumour suppres sor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Adult Urol 46:334Google Scholar
  17. 17.
    Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang Z-F, Sheinfeld J, Fair WR, Herr HW, Reuter VE (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85:53PubMedGoogle Scholar
  18. 18.
    Sarkis AS, Dalbagni G, Cordon-Cardo C (1994) Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. Br J Urol 73:533PubMedGoogle Scholar
  19. 19.
    Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang Z-F, Schultz PR, Cordon-Cardo C, Scher HI (1995) Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 13:1384PubMedGoogle Scholar
  20. 20.
    Schmitz-Dräger BJ, Roeyen CRC, Grimm M-O, Gerharz C-D, Decken K, Schulz WA, Bültel H, Makri D, Ebert T, Ackermann R (1994) P53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol 12:79PubMedGoogle Scholar
  21. 21.
    Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, Jonas U (1995) P53 immunohistochemistry as an independent prognostic factor for transitional cell carcinoma of the bladder. Br J Cancer 71:201PubMedGoogle Scholar
  22. 22.
    Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P (1996) Prevalence and clinical significance ofHER-2/neu, p53 andRb expression in primary superficial bladder cancer. J Urol 155:1794Google Scholar
  23. 23.
    Thomas D, Robinson MC, Charlton R, Wilkinson S, Shenton BK, Neal DE (1993) P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. Br J Urol 73:533Google Scholar
  24. 24.
    Underwood MA, Reeves J, Smith G, Gardiner DS, Bartlett J, Cooke TG (1996) Overexpression of p53 protein and its significance for recurrent progressive bladder tumours. Br J Urol 77:659PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • F. C. Burkhard
    • 1
  • R. Markwalder
    • 2
  • G. N. Thalmann
    • 1
  • U. E. Studer
    • 1
  1. 1.Department of UrologyUniversity of BerneBerneSwitzerland
  2. 2.Department of PathologyUniversity of BerneBerneSwitzerland

Personalised recommendations